FOSUN 复星

復星國際有限公司

FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability)

(Stock Code: 00656)

H SHARE RSU FIRST GRANT UNDER THE 2025 H SHARE RSU SCHEME OF FOSUN PHARMA

References are made to the announcement of Fosun International Limited (the "**Company**") dated 24 August 2025 (the "**Announcement**") and the circular of the Company dated 25 September 2025 (the "**Circular**") in relation to, among other things, the proposed adoption of the 2025 H Share RSU Scheme of Fosun Pharma and/or the proposed H Share RSU First Grant. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement and the Circular.

The 2025 H Share RSU Scheme and the Conditional H Share RSU Grant were approved by the Fosun Pharma Shareholders at the Fosun Pharma EGM held on 23 October 2025, and the 2025 H Share RSU Scheme was approved by the Shareholders at the EGM of the Company held on the same date. On 4 November 2025, the Fosun Pharma Board resolved that (i) as 6 proposed grantees had ceased to be employed by the Fosun Pharma Group and thus ceased to be Eligible Employees, the number of H Share RSU Grantees under the H Share RSU First Grant shall be reduced to 195 from 201, and the number of RSUs under the H Share RSU First Grant shall be reduced to 10,589,500 from 10,696,400; and (ii) the H Share RSU Grant Date of the H Share RSU First Grant shall be 4 November 2025, and the H Share RSU First Grant shall be made on such date.

Therefore, the terms of the H Share RSU First Grant have been updated to reflect the following:

H Share RSU Grant Date:	4 November 2025
Grantees:	195 Eligible Employees
Number of RSUs granted:	10,589,500 RSUs (which represent the right to receive 10,589,500 Restricted H Shares, representing approximately 1.9575% of the total number of H Shares of Fosun Pharma ("**H Shares**") in issue (excluding any treasury shares) as at the date of this announcement)

Closing price of the H Shares on the date of grant:	HK$22.62 per H Share
Financial assistance:	As at the date of this announcement, there are no arrangements for Fosun Pharma or any of its subsidiaries to provide financial assistance to any H Share RSU Grantee to facilitate his or her purchase of H Shares under the H Share RSU First Grant under the H Share RSU Scheme.

Save as disclosed above, the terms of the H Share RSU First Grant as disclosed in the Announcement remain unchanged.

Number of H Shares Available for Future Grant

The total number of H Shares which may be issued and transferred out of treasury in respect of all RSUs to be granted under the H Share RSU Scheme and all options and awards to be granted under any other share scheme(s) of Fosun Pharma under the H Share Scheme Mandate Limit is 54,097,150 H Shares, representing approximately 10% of the total number of H Shares in issue (excluding any treasury shares) as at the Adoption Date.

Subsequent to the H Share RSU First Grant of 10,589,500 RSUs, the number of H Shares available for future grant under the H Share Scheme Mandate Limit is 43,507,650 H Shares as at the date of the H Share RSU First Grant.

To the best knowledge of the Directors after having made all reasonable enquiries, as at the date of this announcement, none of the grantees under the H Share RSU First Grant is (i) a Director, chief executive or substantial shareholder (as defined under the Hong Kong Listing Rules) of the Company or an associate of any of them; (ii) a participant with options and awards granted and to be granted exceeding the 1% individual limit under Rule 17.03D(1) of the Hong Kong Listing Rules; or (iii) a related entity participant or service provider (as defined under the Hong Kong Listing Rules) with options and awards granted and to be granted in any 12-month period exceeding 0.1% of the issued H Shares (excluding treasury shares).

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

4 November 2025

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Huang Zhen and Mr. Pan Donghui; the non-executive directors are Mr. Li Shupei, Mr. Li Fuhua and Mr. Luo Yuanli; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Dr. Lee Kai-Fu and Ms. Tsang King Suen Katherine.